Clinical Trial Update: Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD [Phase 3]

View source ↗

Summary

The document summarizes long-term safety data from a Phase 3 study of PRC-063 in adolescents and adults with ADHD. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• PRC-063 (PRC-063)

Snippet

Sponsor: Rhodes Pharmaceuticals, L.P. | Conditions: ADHD | Phase 3 | Status: COMPLETED